Connection

Co-Authors

This is a "connection" page, showing publications co-authored by JUN YAO and MIEN-CHIE HUNG.
Connection Strength

2.818
  1. Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. J Biol Chem. 2022 04; 298(4):101817.
    View in: PubMed
    Score: 0.207
  2. Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nat Commun. 2021 05 13; 12(1):2788.
    View in: PubMed
    Score: 0.196
  3. TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. J Clin Invest. 2021 04 15; 131(8).
    View in: PubMed
    Score: 0.195
  4. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021 02 05; 12(1):832.
    View in: PubMed
    Score: 0.192
  5. Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun. 2020 Jan 29; 11(1):673.
    View in: PubMed
    Score: 0.179
  6. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun. 2019 11 08; 10(1):5114.
    View in: PubMed
    Score: 0.176
  7. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell. 2018 04 09; 33(4):752-769.e8.
    View in: PubMed
    Score: 0.158
  8. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell. 2018 02 12; 33(2):187-201.e10.
    View in: PubMed
    Score: 0.156
  9. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016 08 30; 7:12632.
    View in: PubMed
    Score: 0.141
  10. Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial-Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity. Cancer Immunol Res. 2016 06; 4(6):552-61.
    View in: PubMed
    Score: 0.137
  11. Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. Am J Transl Res. 2015; 7(6):1009-20.
    View in: PubMed
    Score: 0.130
  12. Definition of PKC-a, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res. 2014 Sep 01; 74(17):4822-35.
    View in: PubMed
    Score: 0.121
  13. Targeting a chemo-induced adaptive signaling circuit confers therapeutic vulnerabilities in pancreatic cancer. Cell Discov. 2024 Oct 29; 10(1):109.
    View in: PubMed
    Score: 0.062
  14. Astrocyte-induced Cdk5 expedites breast cancer brain metastasis by suppressing MHC-I expression to evade immune recognition. Nat Cell Biol. 2024 Oct; 26(10):1773-1789.
    View in: PubMed
    Score: 0.062
  15. BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers. Cancer Discov. 2024 Aug 02; 14(8):1476-1495.
    View in: PubMed
    Score: 0.061
  16. Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer. Nat Commun. 2024 Apr 11; 15(1):3149.
    View in: PubMed
    Score: 0.060
  17. Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation. Cell Metab. 2023 08 08; 35(8):1457-1473.e13.
    View in: PubMed
    Score: 0.057
  18. Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Sci Adv. 2023 02 03; 9(5):eadd6995.
    View in: PubMed
    Score: 0.055
  19. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Sci Transl Med. 2022 11 02; 14(669):eabo1981.
    View in: PubMed
    Score: 0.054
  20. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nat Commun. 2021 12 06; 12(1):7041.
    View in: PubMed
    Score: 0.051
  21. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol. 2021 04; 34(4):710-719.
    View in: PubMed
    Score: 0.047
  22. Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases. Sci Transl Med. 2020 05 27; 12(545).
    View in: PubMed
    Score: 0.046
  23. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019 07; 20(7):835-851.
    View in: PubMed
    Score: 0.043
  24. LncRNAs-directed PTEN enzymatic switch governs epithelial-mesenchymal transition. Cell Res. 2019 04; 29(4):286-304.
    View in: PubMed
    Score: 0.042
  25. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017 12 01; 127(12):4498-4515.
    View in: PubMed
    Score: 0.038
  26. The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 to?hyperactivate AKT?and confer resistance to AKT?inhibitors. Nat Cell Biol. 2017 03; 19(3):238-251.
    View in: PubMed
    Score: 0.036
  27. A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis. Nat Cell Biol. 2017 02; 19(2):106-119.
    View in: PubMed
    Score: 0.036
  28. 14-3-3? turns TGF-?'s function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. Cancer Cell. 2015 Feb 09; 27(2):177-92.
    View in: PubMed
    Score: 0.032
  29. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell. 2013 Mar 18; 23(3):316-31.
    View in: PubMed
    Score: 0.028
  30. 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res. 2009 Apr 15; 69(8):3425-32.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.